Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 4Unknown 3Recruiting 2Enrolling by invitation 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 77Breast Neoplasms 46Colorectal Neoplasms 42Neoplasms 41Neoplasm Metastasis 34Melanoma 31Multiple Myeloma 30Prostatic Neoplasms 29Recurrence 28Stomach Neoplasms 27Pancreatic Neoplasms 27Squamous Cell Carcinoma of Head and Neck 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Lung Neoplasms 26Carcinoma, Renal Cell 25Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 22Leukemia, Myeloid, Acute 22Triple Negative Breast Neoplasms 21Lymphoma, Non-Hodgkin 21Lymphoma, Follicular 21Leukemia, Lymphocytic, Chronic, B-Cell 19Glioblastoma 19Myelodysplastic Syndromes 17Uterine Cervical Neoplasms 16Lymphoma 16Colonic Neoplasms 15Carcinoma, Transitional Cell 15Lymphoma, Mantle-Cell 14Leukemia 14

Interventions

pembrolizumab 1liposomal doxorubicin 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Adenoviridae Infections × Clear all
NCT05271318 2026-05-05

PROTA

TILT Biotherapeutics Ltd.

Phase 1/2 Active not recruiting
29 enrolled

Adenoviridae Infections

NCT03475212 2025-05-11

ACES

Pediatric Transplantation & Cellular Therapy Consortium

Phase 1/2 Active not recruiting
52 enrolled

Primary Immunodeficiency Diseases, Adenoviridae Infections, Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡